18 results on '"Benucci,Maurizio"'
Search Results
2. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study
3. Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koopset al
4. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD
5. Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching
6. Detection of myositis-specific antibodies: additional notes
7. Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke
8. Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?
9. Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description
10. Anti Etanercept and anti SB4 antibodies detection: impact of the assay method
11. Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al.
12. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.
13. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study
14. Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.
15. Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?
16. Detection of myositis-specific antibodies: additional notes.
17. Additional comment to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Scherlinger and Schaeverbeke.
18. Response to: 'Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRA main and extension studies: utility of laboratory methods description' by Francesca Meacci et al.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.